Bharat Biotech aims at billion Covaxin doses a year, phase-3 trials in Oct

Firm also ties up with Washington University's school of medicine for intransal vaccine for Covid-19

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Premium

Phase-3 trials are pivotal and companies need to prove safety and efficacy of the vaccines in those trials

Aneesh Phadnis Mumbai
Bharat Biotech plans to start phase-3 clinical trials of its indegeniously developed Covid-19 vaccine (Covaxin) in October and is in talks with partners to expand its manufacturing footprint to produce one billion doses annually.

The company, on Wednesday, also announced a tie-up with Washington University's school of medicine to develop a novel intransal vaccine for Covid-19 that would enable to overcome challenges in dosage administration. The company will also distribute the intransal vaccine in all markets except US, Japan and Europe.

"We have completed phase I clinical trials of Covaxin and are getting ready to submit data to the Drug

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 23 2020 | 6:44 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com